PREVIOUS
✖
TMC BART Trial
December 13 , 2025
15 hrs 0 min
8
0
- Tata Memorial Centre (TMC) researchers have showed in the Bladder Adjuvant Radiotherapy (BART) trial that post-surgery radiation therapy significantly lowers pelvic recurrence in high-risk bladder cancer patients.
- The BART trial was conducted from 2016 to 2024 and included over 150 patients.
- The study focused on muscle-invasive bladder cancer (MIBC) following radical cystectomy (surgical removal of the bladder).
- Radiation therapy reduced pelvic cancer relapse from 25% to under 10%.
- Modern precision techniques, such as Intensity Modulated Radiation Therapy (IMRT), minimized side effects.
- High-risk patients benefiting most were those with advanced tumour stages, positive lymph nodes, or positive surgical margins.
Leave a Reply
Your Comment is awaiting moderation.